Indications
Lucentis is indicated in adults for: The treatment of neovascular (wet) age-related macular degeneration (AMD) The treatment of visual impairment due to choroidal neovascularisation (CNV) The treatment of visual impairment due to diabetic macular oedema (DME) The treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO)
Composition
- Active substance
- ranibizumab
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Lucentis
- Active substance
- ranibizumab
- ATC code
- S01LA04
- Group
- Sensory organs
- Therapeutic area
- Wet Macular Degeneration, Macular Edema, Diabetes Complications, Myopia, Degenerative, Choroidal Neovascularization